Outcome of diode laser vaporization for high risk patients with ‎benign prostatic hyperplasia.

Abstract

Objective: To determine the outcome of laser vaporization of prostate using diode at 980/1470 nm for the treatment of BPH among high risk patients. Study Design: Longitudinal Observational Study. Setting: Shalamar Hospital, Lahore. Period: June 2009 till June 2022. Material & Methods: Total of 500 patients with associated co-morbid illnesses and benign prostate hyperplasia not responding to medical therapy, failed trial without catheter, chronic urinary retention, refusal for TURP were assessed for eligibility to enter the study. Inclusion criteria were patients with refractory urinary retention, chronic urinary retention, failure of previous medical treatment. Exclusion criteria were patients with neurogenic bladder, carcinoma of prostate, carcinoma of bladder, abnormal digital rectal examination, known neurological disorder or history of spinal cord injury also were excluded from study. Results: The patients’ mean age ‎was 68.57 ± 7.98 years, Baseline mean maximum urinary flow rate was 5.57±‎2.44 mL/s, post void residual was 130.91‎±‎24.18 mL, and international prostate symptom score was 26.09 ‎±‎2.40 at preoperative. At 3 months follow-up, Qmax was 23.31±‎8.0, PVR was 22.43±5.21 and IPSS was 7.27‎±‎1.42. On the other hand, mean Qmax was 25.83‎±‎6.84 mL/s, PVR was 18.38‎±‎4.53 mL, and IPSS was 5.29 ±‎0.61 at 6 months follow-up. Conclusion:Treatment of BPH by 980/1470 nm diode laser have effective and safe clinical outcome for high risk patients as we found significant improvements in Qmax, IPSS, and PVR at 3 months and 6 months follow up.